




Division of Medical Services Pharmacy Program

P.O. Box 1437, Slot S415 · Little Rock, AR 72203-1437
501-683-4120 · Fax: 501-683-4124 or 1-800-424-5851



ARKANSAS MEDICAID DUR/DRC BOARD QUARTERLY DRUG UPDATE

April 19, 2023 8:30 A.M. – 12:30 P.M.

VIRTUAL ZOOM MEETING

****TENTATIVE AGENDA IS SUBJECT TO CHANGE****

I. OUTSIDE SPEAKERS

DUR/DRC Board Bylaws, Section 7.02 Outside Speakers -- Outside speakers with clinical or scientific credentials or patient experience pertinent to a product or topic that is posted on the upcoming DUR/DRC Board meeting agenda may request to speak on that product or topic. Requests to speak at the DUR/DRC Board meeting must be made in writing to the DUR Chairperson at least two (2) weeks before the DUR/DRC Board meeting date, and should include:

1. The speaker's name, title, relevant credentials, and organization;
2. Contact information for the speaker including address, telephone number, and email;
3. The agenda item(s) which the speaker intends to address;
4. Prepared comments; and
5. Any educational materials for Board members in advance of the meeting.

This information shall be included in information sent to Board members two (2) weeks prior to the Board meeting. Presentations or public comments given at the DUR/DRC Board meeting are limited to a total of six (6) minutes per drug, which may be shared by multiple speakers. This time limit does not include responses to any questions raised by DUR/DRC Board members during the course of the meeting.

A copy of the proposed criteria for the specific agenda item on which an individual requests to speak may be requested from the Chairperson three (3) weeks prior to the DUR/DRC Board meeting. The information will be in draft form and may be changed by the DUR/DRC Board prior to being finalized. As such, the draft criteria should not be shared with clinicians or patients.

II. UNFINISHED / OLD BUSINESS AND GENERAL ORDERS / AND PROPOSALS TO REVISE PREVIOUS CRITERIA

- A. ANNOUNCEMENTS
- B. APPROVAL OF THE MINUTES FROM THE PREVIOUS MEETING.
- C. UPDATE ON SYSTEM EDITS, IMPLEMENTATIONS, OR FOLLOW-UP ITEMS.
 - 1) Follow-up items from January 18, 2023 DUR/DRC Board: None
 - 2) Implementation information from January 18, 2023 DUR/DRC Board
- D. GENERAL INFORMATION
 - 1) Opioid utilization update
 - 2) Polypharmacy update
- E. PDL CLASS REVIEW WITHOUT CRITERIA
- F. PDL CLASS REVIEW WITH CRITERIA
 - 1) Point-of-sale edits for hypoglycemic agents
 - 2) New PDL class for pituitary suppressive agents (LHRH) with criteria discussion
- G. PROPOSED CHANGES TO EXISTING CRITERIA AND EDITS, INCLUDING POINT OF SALE (POS) CRITERIA, MANUAL REVIEW PA CRITERIA, OR CLAIM EDITS:
 - 1) Point-of-sale edits for cystic fibrosis transmembrane conductance regulator (CFTR) agents
 - 2) Approval criteria for Polymyalgia Rheumatica (new indication for Kevzara®) in TIMS class

III. NEW BUSINESS

- A. PROPOSED NEW CLINICAL POINT OF SALE CRITERIA WITH OR WITHOUT ADDITIONAL CLAIM EDITS:
 - 1) Point-of-sale edits discussion for certain non-preferred anticonvulsants
- B. MANUAL REVIEW PROPOSED CRITERIA WITH OR WITHOUT ADDITIONAL CLAIM EDITS:
 - 1) ALS medications
 - 2) Krazati™ (adagrasib) tablet
 - 3) Sunlenca® (lenacapavir sodium) tablet
 - 4) Jaypirca™ (pirtobrutinib) tablet
 - 5) Orserdu™ (elacestrant) tablet
 - 6) Dartisla ODT® (glycopyrrolate)
 - 7) Filspari™ (sparsentan) tablet
- C. PROPOSED NEW CLAIM EDITS (QUANTITY, DAILY DOSE, ACCUMULATION, GENDER, AGE): None
- D. ProDUR REPORT UPDATE
- E. RDUR REPORT UPDATE

<https://humanservices.arkansas.gov/>

Protecting the vulnerable, fostering independence and promoting better health